In 909 patients with untreated CLL, fixed-duration venetoclax-obinutuzumab or venetoclax-ibrutinib was noninferior to continuous ibrutinib for 3-year PFS (81.1% and 79.4% vs 81.0%; HR 0.87 and 0.84) at a prespecified interim analysis.
RCTn = 909
Al-Sawaf et al. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia